DARZALEX® + Vd Demonstrated Superior Efficacy vs. Vd Alone


DARZALEX® + Velcade® (bortezomib) + dexamethasone

Significant improvement in PFS using DARZALEX®-based triplet therapy1



PFS=progression-free survival; HR=hazard ratio.

Complete response rate more than doubled with DARZALEX® + Vd

The majority (79%) of patients responded to DARZALEX® + Vd1



PR=partial response; VGPR=very good partial response; CR=complete response; sCR=stringent complete response.

Deeper and sustained responses were demonstrated with DARZALEX® + Vd vs Vd1

  • With DARZALEX® + Vd, median time to first response was 0.8 months (range: 0.7 to 4 months), median time to VGPR or better was 3.5 months (95% CI: 2.8, 4.2), and median time to CR or better was not yet reached (95% CI: 12.0, not estimable [NE])1,2

Daratumumab (DARZALEX®) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred Category 1* therapeutic option for previously treated multiple myeloma

*Category 1=based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.